Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 140 of the 141 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia. PARTICIPANTS: The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines. CONCLUSIONS: Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have reported that 44-62% of cases experience a reversal of hypogonadism, usually within 6 months after starting treatment (225,226).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [226]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Persistently elevated prolactin levels can indicate the presence of pituitary tumors, such as prolactinomas”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“development and implementation of evidence-based guidelines (1).”
Fernandez, A., Karavitaki, N., & Wass, J. A. H. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03667.x · Cited by 1,115
Self-citationHigh Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
Daly, A. F., Rixhon, M., Adam, C., Dempegioti, A., Tichomirowa, M. A., & Beckers, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1668 · Cited by 1,025
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Self-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Casanueva, F. F., Molitch, M. E., Schlechte, J. A., Abs, R., Bonert, V., Bronstein, M. D., Brue, T., Cappabianca, P., Colao, A., Fahlbusch, R., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02562.x · Cited by 829
Self-citationAdvances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
A Radioimmunoassay for Human Prolactin
Hwang, P., Guyda, H., & Friesen, H. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.8.1902 · Cited by 752 · cited 2×
“1970 permitted development of RIAs (4, 5), which en-”
Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., & Scanlon, M. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311403 · Cited by 699
Cited by
Items 201–300 of 1,001
The 3PAs: An Update on the Association of Pheochromocytomas, Paragangliomas, and Pituitary Tumors
Xekouki, P., Brennand, A., Whitelaw, B., Pacák, K., & Stratakis, C. A. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0661-0341 · Cited by 50
Ma, Q., Su, J., Li, Y., Wang, J., Long, W., Luo, M., & Liu, Q. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00636 · Cited by 43
Mascarenhas, M., Jeve, Y. B., Polański, Ł., Sharpe, A., Yasmin, E., & Bhandari, H. M. (2021) · Human Fertility · doi:10.1080/14647273.2021.1905886 · Cited by 47
“Hyperprolactinaemia should be managed as per recommended guidelines (Melmed et al., 2011).”
BackgroundEarly Prediction of Long-Term Response to Cabergoline in Patients with Macroprolactinomas
Lee, Y., Ku, C. R., Kim, E. H., Hong, J. W., Lee, E. J., & Kim, S. H. (2014) · Endocrinology and Metabolism · doi:10.3803/enm.2014.29.3.280 · Cited by 42
Macroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes
Lambert, K., Rees, K., Seed, P. T., Dhanjal, M. K., Knight, M., McCance, D. R., & Williamson, C. (2016) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000001747 · Cited by 47
Burke, W. T., Penn, D. L., Castlen, J. P., Donoho, D. A., Repetti, C. S., Iuliano, S., Barkhoudarian, G., & Laws, E. R. (2019) · Journal of neurosurgery · doi:10.3171/2019.3.jns19121 · Cited by 42
Bromocriptine therapy: Review of mechanism of action, safety and tolerability
Naz, F., Malik, A. R., Riaz, M., Mahmood, Q., Mehmood, M. H., Rasool, G., Mahmood, Z., & Abbas, M. (2022) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13678 · Cited by 54
“Therefore, the probabilities of pregnancy in bromocriptine treated patients become fairly common and more than 90% women with anovulation has been reported to restore ovulation.(50,51) However, macroprolactinomas (>10 mm diameter) require prolonged bromo-”
BackgroundSousa, S. M. C. D. (2022) · Endocrine Oncology · doi:10.1530/eo-21-0038 · Cited by 45
“Treatment resistance may be partial, with therapeutic responses evident only upon significant DA dose escalation (Melmed et al. 2011).”
InfluentialTang, C., Sun, R., Wen, G., Zhong, C., Yang, J., Zhu, J., Cong, Z., Luo, X., & Ma, C. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1526-0 · Cited by 41
Park, Y. W., Eom, J., Kim, S., Kim, H., Ahn, S. S., Ku, C. R., Kim, E. H., Lee, E. J., Kim, S. H., & Lee, S. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab159 · Cited by 44
Screening for Hormonal, Monogenic, and Syndromic Disorders in Obese Infants and Children
Mason, K. A., PAGE, L. C., & Balikcioglu, P. G. (2014) · Pediatric Annals · doi:10.3928/00904481-20140825-08 · Cited by 52
Somatostatin and Somatostatin Receptors in Tumour Biology
Kumar, U. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010436 · Cited by 55
Importance of cannulated prolactin test in the definition of hyperprolactinaemia
Whyte, M., Pramodh, S., Srikugan, L., Gilbert, J. A., MIELL, J. P., Sherwood, R. A., McGregor, A., & Aylwin, S. J. B. (2014) · Pituitary · doi:10.1007/s11102-014-0576-7 · Cited by 40
Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia
Montejo, A. L., Arango, C., Bernardo, M., Carrasco, J. L., Crespo‐Facorro, B., Cruz, J. J., del Pino, J., Escudero, M. A. G., García‐Rizo, C., González-Pinto, A. M., et al. (2016) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2016.06.001 · Cited by 48
Males with prolactinoma are at increased risk of incident cardiovascular disease
Toulis, K. A., Robbins, T., Reddy, N., Kumarendran, B., Gokhale, K. M., Wijesinghe, H. E., Cheng, K. K., Karavitaki, N., Wass, J. A. H., & Nirantharakumar, K. (2017) · Clinical Endocrinology · doi:10.1111/cen.13498 · Cited by 41
Self-citationProlactinoma through the female life cycle
Eschler, D. C., Javanmard, P., Cox, K., & Geer, E. B. (2017) · Endocrine · doi:10.1007/s12020-017-1438-7 · Cited by 44
Magnetic resonance imaging in the management of prolactinomas; a review of the evidence
Varlamov, E. V., Hinojosa‐Amaya, J. M., & Fleseriu, M. (2019) · Pituitary · doi:10.1007/s11102-019-01001-6 · Cited by 40
The risks of medical treatment of prolactinoma
Castinetti, F., Albarel, F., Amodru, V., Cuny, T., Dufour, H., Graillon, T., Morange, I., & Brue, T. C. (2020) · Annales d Endocrinologie · doi:10.1016/j.ando.2020.12.008 · Cited by 40
Managing Prolactinomas during Pregnancy
Almalki, M., ALZAHRANI, S. H., Alshahrani, F., Alsherbeni, S., Almoharib, O., Aljohani, N., & Almagamsi, A. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00085 · Cited by 40
Prolactinomas: evolution after menopause
Mallea-Gil, S., Manavela, M. P., Alfieri, A., Ballarino, M. C., Chervín, A., Danilowicz, K., Diez, S., Day, P., García-Basavilbaso, N., Glerean, M., et al. (2016) · Archives of Endocrinology and Metabolism · doi:10.1590/2359-3997000000138 · Cited by 40
Sala, E., Buttoni, P. B., Malchiodi, E., Verrua, E., Carosi, G., Profka, E., Rodari, G., Filopanti, M., Ferrante, E., Spada, A., et al. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0483-z · Cited by 39
Approach to the Patient with Persistent Hyperprolactinemia and Negative Sellar Imaging
Glezer, A., & Bronstein, M. D. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2976 · Cited by 39
Clinical guidelines for diagnosis and treatment of prolactinoma and hyperprolactinemia
Halperín, I., Gómez, R. C., Mouriz, M. G., & García-Agulló, D. O. (2013) · Endocrinología y Nutrición (English Edition) · doi:10.1016/j.endoen.2012.11.009 · Cited by 39
“When the results are doubtful (mild PRL elevations) or inconsistent with the clinical picture, the measurement may be repeated on samples taken at 15--20 min intervals to minimize the effect of pulsatility.(3,4) Dynamic tests (TRH, l-dopa, domperidone, etc.”
BackgroundInfluentialLiu, X., Liu, Y., Gao, J., Feng, M., Bao, X., Deng, K., Yao, Y., & Wang, R. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.02.188 · Cited by 38
Predictive modeling for pituitary adenomas: single center experience in 501 consecutive patients
Pappy, A. L., Savinkina, A. A., Bicknese, C., Neill, S. G., Oyesiku, N. M., & Ioachimescu, A. G. (2019) · Pituitary · doi:10.1007/s11102-019-00982-8 · Cited by 41
Aggressive prolactinomas: how to manage?
Lasolle, H., Ilie, M. D., & Raverot, G. (2019) · Pituitary · doi:10.1007/s11102-019-01000-7 · Cited by 39
Anna, B., Musolino, N. R. D. C., Gadelha, M. R., Marques, C., de Castro, M., Elias, P. C. L., Vilar, L., Lyra, R., Martins, M. R. A., Quidute, A. R. P., et al. (2019) · Pituitary · doi:10.1007/s11102-019-01008-z · Cited by 48
Aggressive pituitary tumors in the young and elderly
Tatsi, C., & Stratakis, C. A. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09534-8 · Cited by 39
Best candidates for dopamine agonist withdrawal in patients with prolactinomas
Ji, M. J., Kim, J. H., Lee, J. H., Lee, J. H., Kim, Y. H., Paek, S. H., Shin, C. S., & Kim, S. Y. (2017) · Pituitary · doi:10.1007/s11102-017-0820-z · Cited by 38
Roke, Y., van Harten, P. N., Franke, B., Galesloot, T. E., Boot, A. M., & Buitelaar, J. K. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283647c33 · Cited by 44
Athanasoulia, A. P., Sievers, C., Ising, M., Brockhaus, A. C., Yassouridis, A., Stalla, G. K., & Uhr, M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0198 · Cited by 38
Hyperprolactinaemia in first episode psychosis - A longitudinal assessment
Lally, J., Ajnakina, O., Stubbs, B., Williams, H. R., Colizzi, M., Carra, E., Fraietta, S., Gardner-Sood, P., Greenwood, K., Atakan, Z., et al. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.07.037 · Cited by 42
Akbari, H., Malek, M., Ghorbani, M., Hashemi, S. M. R., Khamseh, M. E., Mehrjardi, A. Z., Emami, Z., & Valojerdi, A. E. (2018) · British Journal of Neurosurgery · doi:10.1080/02688697.2018.1429569 · Cited by 38
“Except for prolactinoma where medical therapy is the treatment of choice, transsphenaid surgery is the treatment of choice.(2) Microscopic transsphenoidal surgery (MTS) has been considered as the standard.”
BackgroundMethodTumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1
Jian, M., Du, Q., Zhu, D., Mao, Z., Wang, X., Feng, Y., Xiao, Z., Wang, H., & Zhu, Y. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0963-4 · Cited by 38
Association of prolactin receptor (PRLR) variants with prolactinomas
Gorvin, C. M., Newey, P. J., Rogers, A., Stokes, V. J., Neville, M. J., Lines, K. E., Ntali, G., Lees, P., Morrison, P. J., Singhellakis, P. N., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy396 · Cited by 42
“Macroprolactinomas in both genders may compress the adjacent optic chiasma and cause a visual field defect (3,4).”
BackgroundInfluentialSerum prolactin levels across pregnancy and the establishment of reference intervals
Hu, Y., Ding, Y., Yang, M., & Xiang, Z. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2017-0644 · Cited by 38
“In 1970, human PRL was isolated from the human pituitary gland for the first time, and PRL was then detected by radioimmunoassay [2].”
BackgroundThe Role of Dopamine Agonists in Pituitary Adenomas
Giraldi, E. A., & Ioachimescu, A. G. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.05.006 · Cited by 38
Hinojosa‐Amaya, J. M., Johnson, N., Gonzalez‐Torres, C., Varlamov, E. V., Yedinak, C. G., McCartney, S., & Fleseriu, M. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.579606 · Cited by 40
Yang, H., Lin, J., Li, H., Liu, Z., Chen, X., & Chen, Q. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.571229 · Cited by 47
“The detection lower limit for PRL was 20 mIU/L and if serum PRL is over 530 mIU/L, it is considered to be hyperprolactinemia (30, 31).”
BackgroundReal-life clinical impact of a five-tiered classification of pituitary tumors
Sahakian, N., Appay, R., Resseguier, N., Graillon, T., Piazzola, C., Laure, C., Figarella-Branger, D. F., Régis, J. M., Castinetti, F., Brue, T. C., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0812 · Cited by 38
ErbB Receptor-Driven Prolactinomas Respond to Targeted Lapatinib Treatment in Female Transgenic Mice
Liu, X., Maya, K., Araki, T., Cooper, O. B., Fukuoka, H., Tone, Y., Tone, M., & Melmed, S. K. (2014) · Endocrinology · doi:10.1210/en.2014-1627 · Cited by 37
Self-citationEren, E., Erdeve, Ş. S., Çakır, E. D. P., Ceylan, L. A., Sağlam, H., & Tarım, Ö. (2011) · Journal of Clinical Research in Pediatric Endocrinology · doi:10.4274/jcrpe.v3i2.14 · Cited by 37
“In adults, medical therapy is recommended even in patients with a macroadenoma and even in the presence of visual field pathology (19).”
BackgroundEarly recognition of aggressive pituitary adenomas: a single-centre experience
Ceccato, F., Regazzo, D., Barbot, M., Denaro, L., Emanuelli, E., Borsetto, D., Rolma, G., Alessio, L., Gardiman, M. P., Lombardi, G., et al. (2017) · Acta Neurochirurgica · doi:10.1007/s00701-017-3396-5 · Cited by 38
“Two-thirdsofpatients revealedCSI,especiallyPRL-secreting adenomas; nevertheless, it isworth remembering that aggressive forms are a small part of all PRL-secreting pituitary adenomas, since they are both controlled with dopamine agonists and early diagnosed [12].”
InfluentialGalm, B. P., Martínez-Salazar, E. L., Swearingen, B., Torriani, M., Klibanski, A., Bredella, M. A., & Tritos, N. A. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0291 · Cited by 39
Česák, T., Póczoš, P., Adamkov, J., Náhlovský, J., Kašparová, P., Gabalec, F., Čelakovský, P., & Choutka, O. (2018) · Pituitary · doi:10.1007/s11102-018-0907-1 · Cited by 44
Micko, A. S. G., Vila, G., Höftberger, R., Knosp, E., & Wolfsberger, S. (2018) · Neurosurgery · doi:10.1093/neuros/nyy385 · Cited by 37
Castro, M. A., Mariño‐Sánchez, F., Cancela, A. A., Fernández, A. G., Duque, S. G., & Berrocal, V. R. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01448-6 · Cited by 38
Macroprolactinemia: new insights in hyperprolactinemia
Kasum, M., Orešković, S., Zec, I., Ježek, D., Tomić, V., Gall, V., & Adžić, G. (2012) · Biochemia Medica · doi:10.11613/bm.2012.020 · Cited by 38
“Because true hyperprolactinemia and macroprolactinemia cannot be reliably distinguished on clinical criteria alone, a Task Force of The Endocrine Society suggested screening for macroprolactin in investigation of asymptomatic hyperprolactinemic subjects (32,33).”
Prolactinomas in children under 14. Clinical presentation and long-term follow-up
Liu, Y., Yao, Y., Xing, B., Lian, W., Deng, K., Feng, M., & Wang, R. (2015) · Child s Nervous System · doi:10.1007/s00381-015-2679-5 · Cited by 35
Prolactin-secreting adenomas: pathogenesis, diagnosis, and management
Fleseriu, M., Varlamov, E. V., Akirov, A., Langlois, F., Petersenn, S., & Melmed, S. K. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00227-x · Cited by 53
Self-citationNo clinically significant valvular regurgitation in long‐term cabergoline treatment for prolactinoma
Halperín, I., Aller, J., Varela, C., Mora, M., Abad, A. Z., Doltra, A., Santos, A. E., Batista, E., García‐Pavía, P., Sitges, M., et al. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04349.x · Cited by 38
Eroukhmanoff, J., Téjédor, I., Potorac, I., Cuny, T., Bonneville, J., Dufour, H., Weryha, G., Beckers, A. M., Touraine, P. A., Brue, T. C., et al. (2017) · European Journal of Endocrinology · doi:10.1530/eje-16-0897 · Cited by 39
Hyperprolactinemia and the Association with All-Cause Mortality and Cardiovascular Mortality
Krogh, J., Selmer, C., Torp-Pedersen, C. T., Gislason, G., & Kistorp, C. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-107243 · Cited by 37
Almalki, M., Aljoaib, N. N., Alotaibi, M. J., Aldabas, B. S., Wahedi, T., Ahmad, M. M., & Alshahrani, F. (2017) · HORMONES · doi:10.14310/horm.2002.1729 · Cited by 36
Effect of cabergoline monotherapy in Cushing’s disease: an individual participant data meta-analysis
Palui, R., Sahoo, J., Kamalanathan, S., Kar, S. S., Selvarajan, S., & Durgia, H. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0936-7 · Cited by 38
González-Rodríguez, A., Labad, J., & Seeman, M. V. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109941 · Cited by 42
Wildemberg, L. E., Fialho, C., & Gadelha, M. R. (2021) · La Presse Médicale · doi:10.1016/j.lpm.2021.104080 · Cited by 36
Pituitary Tumor Management in Pregnancy
Araújo, P. B., Neto, L. V., & Gadelha, M. R. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.10.015 · Cited by 37
“Periodic evaluation of prolactin levels offers no diagnostic benefit and is not recommended (Box 2).(16)”
BackgroundMethodInfluentialMelmed, S. K., & Kleinberg, D. L. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00009-2 · Cited by 38
Self-citationHyperprolactinaemia – a problem in patients from the reproductive period to the menopause
Pałubska, S., Adamiak, A., Winkler, I., Romanek-Piva, K., Rechberger, T., & Gogacz, M. (2017) · Menopause Review/Przegląd Menopauzalny · doi:10.5114/pm.2017.67364 · Cited by 45
“It also occurs in men but four times less frequently [11, 12].”
BackgroundSurgery for Prolactinomas to Date
Buchfelder, M., Zhao, Y., & Schlaffer, S.-M. (2019) · Neuroendocrinology · doi:10.1159/000497331 · Cited by 35
Epidemiology of Functioning Pituitary Adenomas
Chin, S. O. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.35.2.237 · Cited by 58
“Although hyperprolactinemia can be caused by various etiologies, including pregnancy, breastfeeding, exercise, stress, renal or thyroid insufficiency, drugs, and pituitary stalk compression by a non-prolactin-producing tumor or other parasellar masses [41], prolactin-producing PAs are considered to be the most clinica…”
BackgroundAdverse body composition and lipid parameters in patients with prolactinoma: a case-control study
Posawetz, A. S., Trummer, C., Pandis, M., Aberer, F., Pieber, T. R., Obermayer-Pietsch, B. M., Pilz, S., & Theiler‐Schwetz, V. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00733-6 · Cited by 37
“In cases of lower prolactin levels in combination with a pituitary macroadenoma on MRI, pituitary stalk compression was considered and ruled out as the main differential diagnosis [13].”
BackgroundHyperprolactinemia, Clinical Considerations, and Infertility in Women on Antipsychotic Medications
Edinoff, A. N., Silverblatt, N. S., Vervaeke, H., Horton, C. C., Girma, E., Kaye, A. D., Kaye, A. M., Kaye, J. S., Garcia, A. J., Neuchat, E. E., et al. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4396 · Cited by 49
Prolactin immunoassay: does the high-dose hook effect still exist?
Raverot, V., Perrin, P., Chanson, P., Jouanneau, E., Brue, T. C., & Raverot, G. (2022) · Pituitary · doi:10.1007/s11102-022-01246-8 · Cited by 35
Second attempt to withdraw cabergoline in prolactinomas: a pilot study
Kwancharoen, R., Auriemma, R. S., Yenokyan, G., Wand, G. S., Colao, A. A. L., & Salvatori, R. (2013) · Pituitary · doi:10.1007/s11102-013-0525-x · Cited by 35
“Medical therapy with dopamine agonist is the treatment of choice in most of the cases [1].”
BackgroundInfluentialOvergaard, M., & Pedersen, S. M. (2017) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2016-0902 · Cited by 35
Chen, H., Fu, J., & Huang, W. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008883.pub2 · Cited by 41
Advances in understanding pituitary tumors
Kopczak, A., Renner, U., & Stalla, G. K. (2014) · F1000Prime Reports · doi:10.12703/p6-5 · Cited by 40
Lương, H. V., Tai, P. T., Nishijo, M., Trung, D. M., Thao, P. N., Son, P. V., Long, N. V. D., Linh, N. T., & Nishijo, H. (2018) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2018.02.094 · Cited by 35
Use of optical fluorescence agents during surgery for pituitary adenomas: current state of the field
Chang, S. W., Donoho, D. A., & Zada, G. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03062-2 · Cited by 34
Walz, P. C., Drapeau, A. I., Shaikhouni, A., Eide, J. G., Rugino, A. J., Mohyeldin, A., Carrau, R. L., & Prevedello, D. M. (2019) · Child s Nervous System · doi:10.1007/s00381-019-04293-y · Cited by 33
MANAGEMENT OF ENDOCRINE DISEASE: Visual morbidity in patients with pituitary adenoma
Lithgow, K. C., Batra, R., Matthews, T., & Karavitaki, N. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0349 · Cited by 40
Updates in the Medical Treatment of Pituitary Adenomas
Gheorghiu, M. L., Negreanu, F. A., & Fleseriu, M. (2019) · Hormone and Metabolic Research · doi:10.1055/a-1066-4592 · Cited by 40
“The primary treatment goal for prolactinomas is to normalize serum PRL levels [4].”
BackgroundInfluentialAthanasoulia, A. P., Ising, M., Pfister, H., Mantzoros, C. S., Stalla, G. K., & Sievers, C. (2012) · Neuroendocrinology · doi:10.1159/000335996 · Cited by 36
Rastogi, A., Bhansali, A. K., Dutta, P. R., Singh, P., Vijaivergiya, R., Gupta, V., Sachdeva, N. K., Bhadada, S. K., & Walia, R. (2013) · Clinical Endocrinology · doi:10.1111/cen.12149 · Cited by 34
Pituitary Incidentalomas: Best Practices and Looking Ahead
Giraldi, E. A., Allen, J. W., & Ioachimescu, A. G. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.10.004 · Cited by 42
The interplay between prolactin and cardiovascular disease
Glezer, A., Santana, M. R., Bronstein, M. D., Donato, J., & Jallad, R. S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1018090 · Cited by 40
“The diagnosis of hyperprolactinemia is defined when a single measurement of serum PRL is above the upper limit of normal, if there was no excessive venipuncture stress (6) and there are several causes of hyperprolactinemia as physiological (pregnancy and lactation), pharmacological (especially antipsychotic drugs), pr…”
BackgroundQian, Q., Liuqin, L., Li, H., Shiwen, Y., Zhongping, Z., Dong-ying, C., Fan, L., Xu, H., Xiuyan, Y., & Ye, Y. (2015) · Journal of Immunology Research · doi:10.1155/2015/316965 · Cited by 39
“The endocrine society clinical practice guideline for diagnosis and treatment of hyperprolactinemia [27] also recommends bromocriptine therapy in patients who experience symptomatic growth of a prolactinoma during pregnancy.”
BackgroundMcGill, J., Shoskes, D. A., & Sabanegh, E. S. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79a.12010 · Cited by 37
Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy
Rastogi, A., Bhadada, S. K., & Bhansali, A. K. (2016) · Gynecological Endocrinology · doi:10.1080/09513590.2016.1254177 · Cited by 33
“(2) Currently, the Endocrine Society Clinical Practice Guidelines suggests that BRC may be continued throughout the pregnancy, especially if the tumor is invasive or is”
BackgroundManagement of antipsychotic-induced hyperprolactinaemia
Gupta, S., Lakshmanan, D. A. M., Khastgir, U., & Nair, R. (2017) · BJPsych Advances · doi:10.1192/apt.bp.115.014928 · Cited by 41
“A significant decrease in the prolactin level or normalisation would confirm the clinical suspicion (Melmed 2011).”
BackgroundHung, Y.-C., Lee, C., Yang, H., Mohammed, N., Kearns, K. N., Nabeel, A. M., Abdelkarim, K., Eldin, R. M. E., El-Shehaby, A. M. N., Reda, W. A. H., et al. (2019) · Journal of neurosurgery · doi:10.3171/2019.4.jns183443 · Cited by 35
Surgical treatment of microprolactinomas: pros
Salvatori, R. (2014) · Endocrine · doi:10.1007/s12020-014-0281-3 · Cited by 33
Management of Incidentally Found Nonfunctional Pituitary Tumors
Molitch, M. E. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.06.003 · Cited by 33
Wang, W., Wang, S., Jiang, Y., Yan, F., Su, T., Zhou, W., Jiang, L., Zhang, Y., & Ning, G. (2015) · Clinical Endocrinology · doi:10.1111/cen.12788 · Cited by 42
Lebduska, E., Beshear, D., & Spataro, B. M. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.10.014 · Cited by 43
Pituitary surgery: experience from a large network in Central Switzerland
Berkmann, S., Fandino, J., Müller-Stich, B. P., Kothbauer, K. F., Henzen, C., & Landolt, H. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13680 · Cited by 34
Management of pituitary incidentaloma
Boguszewski, C. L., Musolino, N. R. D. C., & Kasuki, L. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.04.002 · Cited by 33
Guo, X., Zhang, R., Zhang, D., Wang, Z., Gao, L., Yao, Y., Deng, K., Bao, X., Feng, M., Xu, Z., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.807054 · Cited by 39
Gruppetta, M., & Vassallo, J. (2016) · Clinical Endocrinology · doi:10.1111/cen.13064 · Cited by 33
Solari, D., Pivonello, R., Caggiano, C., Guadagno, E., Chiaramonte, C., Miccoli, G., Cavallo, L. M., De, M. D. B., Colao, A., & Cappabianca, P. (2019) · World Neurosurgery · doi:10.1016/j.wneu.2019.03.049 · Cited by 37
Tirosh, A., Benbassat, C. A., & Shimon, I. (2015) · Endocrine Practice · doi:10.4158/ep15804.or · Cited by 33
Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses
Araújo, C. S., Marques, O., Almeida, R., & Santos, M. J. (2018) · Endocrine · doi:10.1007/s12020-018-1703-4 · Cited by 31
Current treatment options for hyperprolactinemia
Faje, A. T., & Nachtigall, L. B. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.806488 · Cited by 31
“Observation is appropriate in individuals with asymptomatic hyperprolactinemia that results from medications or occurs in the context of a pituitary microadenoma [49].”
BackgroundGheorghiu, M. L., & Fleseriu, M. (2017) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2017.476 · Cited by 33
“unavailable, unsuccessful, or not tolerated (2-5).”
BackgroundBreil, T., Lorz, C., Choukair, D., Mittnacht, J., Inta, I. M., Klose, D., Jesser, J., Schulze, E., & Bettendorf, M. (2018) · Hormone Research in Paediatrics · doi:10.1159/000486280 · Cited by 31
Locatelli, D., Veiceschi, P., Castelnuovo, P., Tanrıöver, N., Evliyaoğlu, O., Canaz, H., Uğurlar, D., & Gazioğlu, N. (2019) · Child s Nervous System · doi:10.1007/s00381-019-04179-z · Cited by 33
Dopamine agonists in prolactinomas: when to withdraw?
Souteiro, P., Belo, S., & Carvalho, D. M. (2019) · Pituitary · doi:10.1007/s11102-019-00989-1 · Cited by 31
Determinants of Surgical Remission in Prolactinomas: A Systematic Review and Meta-Analysis
Wright, K. E., Chaker, L., Pacione, D. R., Sam, K. T., Feelders, R. A., Xia, Y., & Agrawal, N. (2021) · World Neurosurgery · doi:10.1016/j.wneu.2021.07.035 · Cited by 31
Metadata
- Authors
- Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Universidade de Santiago de Compostela (ES)
- VA Palo Alto Health Care System (US)
- New York University (US)
- University of Iowa (US)
- Churchill Hospital (GB)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-02
- Volume
- 96
- Issue
- 2
- Pages
- 273-288
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2019055295
- Semantic Scholar
- 43454263bc46394124a75b19ce2b73452ff5e993
- Cited by
- 1,844
- References
- 141
- Citations by year
- 2026: 133 · 2025: 125 · 2024: 141 · 2023: 150 · 2022: 186 · 2021: 170 · 2020: 138 · 2019: 148 · 2018: 103 · 2017: 107 · 2016: 102 · 2015: 97 · 2014: 76 · 2013: 66 · 2012: 71
- FWCI
- 61.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Funders
- U.S. Department of Defense
- Eli Lilly and Company
- Pfizer
- Teva Pharmaceutical Industries
- European Society of Endocrinology
- Novo Nordisk
- Ipsen
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- hyperprolactinemia, prolactinoma, drug-induced hyperprolactinemia, prolactinoma treatment, pregnancy
- MeSH terms
- Adult, Female, Humans, Hyperprolactinemia, Pituitary Neoplasms, Pregnancy, Prolactinoma, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.